Fed. Circ. Flips Noninfringement Judgment In Allegra IP Row

Law360, New York (May 20, 2013, 5:34 PM EDT) -- Aventis Pharmaceuticals Inc. and Albany Molecular Research Inc. on Monday convinced the Federal Circuit to reverse a noninfringement judgment over an Albany Molecular patent covering processes used to make a purer form of a key ingredient in allergy medication, including Sanofi-Aventis U.S.'s Allegra.

A Federal Circuit panel on Monday granted the bid by Albany Molecular, which was assigned the patent, and Aventis, the licensee for the patent, to reverse a stipulated noninfringement judgment in a New Jersey federal court. That judgment followed a January 2011 opinion...
To view the full article, register now.